Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

ClinicalTrials.gov ID: NCT03698331

Public ClinicalTrials.gov record NCT03698331. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

Study identification

NCT ID
NCT03698331
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Neurocrine Biosciences
Industry
Enrollment
89 participants

Conditions and interventions

Interventions

  • Valbenazine Drug
  • Placebo oral capsule Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 13, 2018
Primary completion
Apr 2, 2019
Completion
Apr 2, 2019
Last update posted
Jun 3, 2020

2018 – 2019

United States locations

U.S. sites
16
U.S. states
9
U.S. cities
14
Facility City State ZIP Site status
Neurocrine Clinical Site Anaheim California 92804
Neurocrine Clinical Site Glendale California 91206
Neurocrine Clinical Site Norwalk California 90650
Neurocrine Clinical Site Oceanside California 92054
Neurocrine Clinical Site San Bernardino California 92108
Neurocrine Clinical Site Hialeah Florida 33012
Neurocrine Clinical Site Hialeah Florida 33013
Neurocrine Clinical Site Hialeah Florida 33018
Neurocrine Clinical Site Honolulu Hawaii 96817
Neurocrine Clinical Site Fort Wayne Indiana 46804
Neurocrine Clinical Site Ann Arbor Michigan 48105
Neurocrine Clinical Site Beechwood Ohio 44122
Neurocrine Clinical Site Oklahoma City Oklahoma 73112
Neurocrine Clinical Site Scranton Pennsylvania 18503
Neurocrine Clinical Site DeSoto Texas 75115
Neurocrine Clinical Site Irving Texas 75062

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03698331, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 3, 2020 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03698331 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →